Alterity Therapeutics (ATH) Price & Analysis

Q: What is Alterity Therapeutics Ltd.’s market cap?

Alterity Therapeutics Ltd.’s market cap is $147.32M.

Q: When is Alterity Therapeutics Ltd.’s upcoming earnings report date?

Alterity Therapeutics Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 210 days.

Q: How were Alterity Therapeutics Ltd.’s earnings last quarter?

Alterity Therapeutics Ltd. released its earnings results on Feb 28, 2025. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.001.

Q: Is Alterity Therapeutics Ltd. overvalued?

According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Alterity Therapeutics Ltd. pay dividends?

Alterity Therapeutics Ltd. does not currently pay dividends.

Q: What is Alterity Therapeutics Ltd.’s EPS estimate?

Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Alterity Therapeutics Ltd. have?

Alterity Therapeutics Ltd. has 9,207,466,000 shares outstanding.

Q: What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?

Alterity Therapeutics Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went down -9.091%.

Q: Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATH

Compare

30 Followers

ATH Stock Chart & Stats

Day’s Range― - ―

52-Week Range<AU$0.01 - AU$0.02

Previous CloseN/A

Volume25.42M

Average Volume (3M)19.35M

Market Cap

$147.32M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta2.96

Next Earnings

Feb 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding9,207,466,000

10 Day Avg. Volume31,766,586

30 Day Avg. Volume19,352,191

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

Alterity Therapeutics News

Alterity Therapeutics reports cash balance of A$40.66M as of June 30

“U.S. FDA Fast Track designation for ATH434 in MSA was the highlight of the recent quarter that also...

1d ago

ATHE

Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial

Alterity announced topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with multiple system atrophy....

3d ago

ATHE

Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study

Alterity Therapeutics (ATHE) announced that a neuroimaging measure developed in Alterity’s Biomarkers of Progression in Multiple System Atrophy...

7d ago

ATHE

Alterity Therapeutics Issues Corporate Presentation with Forward-Looking Statements

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics has released a corporate presentation that includes...

20h ago

Alterity Therapeutics Advances MSA Treatment with FDA Fast Track Designation

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics has received U.S. FDA Fast...

2d ago

Buy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Alterity Therapeutics, with...

2d ago

ATHE

Alterity Therapeutics Reports Promising Phase 2 Results for MSA Treatment

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics announced positive topline results from its open-label...

4d ago

Alterity Therapeutics Unveils New MRI Endpoint for MSA Diagnosis and Progression

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has announced the publication of...

8d ago

Alterity Therapeutics Expands Market Presence with New Securities Quotation

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics Limited has announced the quotation of 95,238...

11d ago

Alterity Therapeutics Announces Quotation of New Securities on ASX

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics Limited announced the quotation of 79,999,800 fully...

15d ago

Alterity Therapeutics Addresses ASX Price Query Amid Market Anticipation

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics Limited has responded to a price query...

18d ago

Alterity Therapeutics Issues 15 Million Unlisted Options to Employees

Alterity Therapeutics ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics Limited announced the issuance of 15 million...

29d ago

Alterity Therapeutics to Update on ATH434 Progress in Upcoming Fireside Chat

The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alterity Therapeutics announced that its CEO, David...

1M ago

Alterity Therapeutics has several presentations featured at 2025 MSA Congress

Alterity Therapeutics (ATHE) “announced that several oral and poster presentations related to Alterity’s clinical programs in Multiple System...

3M ago

ATHE

ATH FAQ

What was Alterity Therapeutics Ltd.’s price range in the past 12 months?

Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.

What is Alterity Therapeutics Ltd.’s market cap?

Alterity Therapeutics Ltd.’s market cap is $147.32M.

When is Alterity Therapeutics Ltd.’s upcoming earnings report date?

Alterity Therapeutics Ltd.’s upcoming earnings report date is Feb 26, 2026 which is in 210 days.

How were Alterity Therapeutics Ltd.’s earnings last quarter?

Alterity Therapeutics Ltd. released its earnings results on Feb 28, 2025. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.001.

Is Alterity Therapeutics Ltd. overvalued?

According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics Ltd. pay dividends?

Alterity Therapeutics Ltd. does not currently pay dividends.

What is Alterity Therapeutics Ltd.’s EPS estimate?

Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alterity Therapeutics Ltd. have?

Alterity Therapeutics Ltd. has 9,207,466,000 shares outstanding.

What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?

Alterity Therapeutics Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATH

Alterity Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-154.88%

Trailing 12-Months

Asset Growth

-56.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alterity Therapeutics Ltd.

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.